Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Institute of Animal Nutrition and Dietetics, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
J Vet Intern Med. 2024 May-Jun;38(3):1370-1376. doi: 10.1111/jvim.17042. Epub 2024 Mar 14.
Corticosteroids are among the most commonly used drugs in cats and are increasingly discussed as a treatment for feline pancreatitis. However, its effects on serum lipase in healthy cats remain unknown.
To evaluate the effects of prednisolone on serum lipase activity and pancreatic lipase immunoreactivity (PLI) in cats.
Seven clinically healthy colony cats, aged 4 to 7 years, with unremarkable CBC/biochemistry panel were studied.
Prospective study: Prednisolone (1.1-1.5 mg/kg, median 1.28 mg/kg PO) was given daily for 7 consecutive days. Lipase activity (LIPC Roche; RI, 8-26 U/L) and PLI (Spec fPL; RI, 0-3.5 μg/L) were determined at day 1 before first treatment and at days 2, 3, 8, 10, and 14. Cats were examined daily. An a priori power analysis indicated that 6 cats were needed to find a biological relevant effect at 1-β = 0.8. Statistical analyses comprised the Friedman test, random intercept regression, and repeated-measures linear regression.
Median (range) day 1 lipase activities and PLI were 22 U/L (14-52 U/L) and 3.2 μg/L (2.3-15.7 μg/L). One cat with abnormally high lipase activity (52 U/L) and PLI (15.7 μg/L) at day 1 continued having elevated lipase activities and PLI throughout the study. Lipase activities and PLI concentrations did not differ significantly among time points regardless of whether the cat with elevated values was included or not. All cats remained healthy throughout the study.
Administration of prednisolone in anti-inflammatory doses does not significantly increase serum lipase activity and PLI concentration.
皮质类固醇是猫最常用的药物之一,并且越来越多地被讨论用于治疗猫胰腺炎。然而,其对健康猫血清脂肪酶的影响尚不清楚。
评估泼尼松龙对猫血清脂肪酶活性和胰腺脂肪酶免疫反应性(PLI)的影响。
七只临床健康的群体猫,年龄 4 至 7 岁,全血细胞计数/生化小组检查无异常。
前瞻性研究:连续 7 天每天给予泼尼松龙(1.1-1.5mg/kg,中位数 1.28mg/kg PO)。在第 1 天(第 1 次治疗前)和第 2、3、8、10 和 14 天,测定脂肪酶活性(LIPC Roche;RI,8-26U/L)和 PLI(Spec fPL;RI,0-3.5μg/L)。每天检查猫。先验功效分析表明,需要 6 只猫才能在 1-β=0.8 时发现具有生物学相关性的效果。统计分析包括 Friedman 检验、随机截距回归和重复测量线性回归。
中位数(范围)第 1 天的脂肪酶活性和 PLI 分别为 22U/L(14-52U/L)和 3.2μg/L(2.3-15.7μg/L)。第 1 天有一只猫的脂肪酶活性(52U/L)和 PLI(15.7μg/L)异常高,在整个研究过程中,其脂肪酶活性和 PLI 持续升高。无论是否包括该值升高的猫,脂肪酶活性和 PLI 浓度在各时间点之间均无显著差异。所有猫在整个研究过程中均保持健康。
给予抗炎剂量的泼尼松龙不会显著增加血清脂肪酶活性和 PLI 浓度。